Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | HSD11B1 | P28845 | 14/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15730553 | 0.73 | HSD11B1 (0.44) | SMN1; SMN2ALDH1A1MEN1KMT2AHSD11B1 | |
| SCHEMBL679382 | 0.73 | ALDH1A1 (0.63) | SMN1; SMN2ALDH1A1MEN1KMT2AHSD11B1 | |
| SCHEMBL678395 | 0.70 | SMN1; SMN2 (0.48) | SMN1; SMN2ALDH1A1MEN1KMT2AHSD11B1 | |
| SCHEMBL4367607 | 0.65 | HSD11B1 (0.47) | SMN1; SMN2HSD11B1CYP3A4 | |
| SCHEMBL4368488 | 0.65 | HSD11B1 (0.47) | SMN1; SMN2HSD11B1CYP3A4 | |
| SCHEMBL15151452 | 0.65 | HSD11B1 (0.47) | SMN1; SMN2HSD11B1CYP3A4 | |
| SCHEMBL4631307 | 0.65 | HSD11B1 (0.47) | SMN1; SMN2HSD11B1CYP3A4 | |
| SCHEMBL10479522 | 0.61 | ALDH1A1 (0.72) | SMN1; SMN2ALDH1A1MEN1KMT2AHSD11B1 | |
| SCHEMBL680166 | 0.60 | — | — | |
| SCHEMBL16582795 | 0.59 | NR1I2 (0.36) | ALDH1A1MEN1KMT2AHSD11B1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110288063-A1 | NOVEL FUSED BRIDGED BICYCLIC HETEROARYL SUBSTITUTED 6-ALKYLIDENE PENEMS AS POTENT BETA-LACTAMASE INHIBITORS | NAEJA PHARMACEUTICAL INC. (CA) | 2011-11-24 | — | — | US | disclosed |
| US-20110288063-A1 | NOVEL FUSED BRIDGED BICYCLIC HETEROARYL SUBSTITUTED 6-ALKYLIDENE PENEMS AS POTENT BETA-LACTAMASE INHIBITORS | NAEJA PHARMACEUTICAL INC. (CA) | 2011-11-24 | — | — | US | disclosed |
| US-20110288063-A1 | NOVEL FUSED BRIDGED BICYCLIC HETEROARYL SUBSTITUTED 6-ALKYLIDENE PENEMS AS POTENT BETA-LACTAMASE INHIBITORS | NAEJA PHARMACEUTICAL INC. (CA) | 2011-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110288063-A1 | NOVEL FUSED BRIDGED BICYCLIC HETEROARYL SUBSTITUTED 6-ALKYLIDENE PENEMS AS POTENT BETA-LACTAMASE INHIBITORS | B2M, MRPL21, RCE1 | SMN1; SMN2 3612/4885ALDH1A1 668/4885MEN1 3202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.